Core Insights - Nokia has partnered with Leonardo to provide mission-critical private wireless networks for public safety and critical infrastructures, enhancing Nokia's position in secure and scalable connectivity solutions [1][3] - The collaboration will integrate Leonardo's MC_linX platform into Nokia's enterprise solutions, facilitating faster deployment and operational readiness while improving emergency response and service reliability [2][9] Company Overview - Nokia is a B2B technology leader focused on creating networks that leverage mobile, fixed, and cloud technologies, with a strong emphasis on innovation through Nokia Bell Labs [6][7] - Leonardo is a major player in Aerospace, Defense, and Security, with a workforce of 60,000 and significant production capabilities across multiple countries, including Italy, the UK, Poland, and the USA [8][10] Technology and Standards - The MC_linX platform is compliant with 3GPP standards, enabling mission-critical communication services over private and commercial LTE/5G networks, which enhances situational awareness and coordinated responses [5][9] - Nokia's Core Enterprise Solutions are designed with low-footprint core modules optimized for mission-critical communications in sectors such as public safety, utilities, and railways [5][9]

Core Insights - FibroBiologics has appointed Jason D. Davis as Chief Financial Officer, bringing over 20 years of experience in public company finance and capital markets to support the company's growth [1][2][3] Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 275 patents issued and pending [1][7] - The company is advancing towards its Phase 1/2 clinical trial for diabetic foot ulcers scheduled for the second half of 2025 [2] Leadership and Experience - Jason D. Davis has a proven track record in leading companies through critical growth phases, including IPOs and capital raising initiatives, which is crucial for FibroBiologics as it moves its lead program into clinical trials [2][3] - Prior to joining FibroBiologics, Mr. Davis served as CFO of Virax Biolabs, where he successfully navigated the company through its IPO and managed multiple capital raises [4] Strategic Vision - Mr. Davis emphasized that FibroBiologics' fibroblast-based platform and strong intellectual property portfolio position the company as a high-growth, high-impact enterprise [4] - The company aims to deliver meaningful value not only for shareholders but also for patients globally [4]

DURHAM, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that the results from its V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for patients at high risk of autologous arteriovenous fistula (AVF) maturation failure with end-stage renal disease were presented in a plenary ses ...

SHELL PLC FIRST QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS June 9, 2025 The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the first quarter 2025 interim dividend, which was announced on May 2, 2025 at US$0.358 per ordinary share. Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elec ...

7201.JP 250.00 JPY 9 June 2025 Japan Autos & Auto Parts Nissan Motor Co Ltd Rating Underperform Price Target Tomohiro Kashimoto +81 3 6777 6975 tomohiro.kashimoto@bernsteinsg.com Nissan: Q1 profits might look better than guidance, but the path to a turnaround is going to be a tough climb What has changed and is unchanged. While we have lowered our forecasts by incorporating company feedback following the FY3/25 results and the impact of US tariffs, we have maintained our price target at ¥250 after making ad ...

M Update Government Bond Auctions: The Month Ahead We review the supply, coupon, and redemption picture for the US, UK, Euro, JPY, AUS, NZ, and CAN government bond markets over the next month. This week, G7 net DV01 is expected to be $109.3mn/bp, compared to an average* $72mn/bp; US $82mn/ bp; Euro $17.1mn/bp; Japan $7mn/bp; UK $1.8mn/bp. The Week Ahead: Net issuance (gross issuance less coupons less redemptions) June 6, 2025 05:38 PM GMT Global Rates Strategy | Global In the euro area, we estimate about €2 ...

Watch LIVE as SpaceX launches the 4th Axiom Space private mission to the International Space Station in low-Earth orbit, AX-4 will launch from Historic Launch Complex 39A at NASA Kennedy Space Center in Florida. Join our community Discord! https://discord.com/invite/xCm9UpDPE4 This coverage is made possible by our amazing community! Consider becoming a The Launch Pad Member and go behind the scenes with early video access, behind the scenes live streams and more! SUBSCRIBE to The Launch Pad! https://www.you ...

EDMONTON, Alberta, June 06, 2025 (GLOBE NEWSWIRE) -- Melcor Developments Ltd. (TSX:MRD), an Alberta-based real estate development and asset management company, announced today that the Toronto Stock Exchange has accepted its notice of intention to make a normal course issuer bid through the facilities of the TSX and on alternative trading systems. The notice provides that Melcor may, during the twelve-month period commencing June 10, 2025 and ending June 9, 2026, purchase for cancellation up to 1,511,087 co ...

TELA Bio (TELA) 2025 Conference June 05, 2025 11:05 AM ET Speaker0 All right. We can kick this off. Hello, everyone. My name is Mike Sarcone. I'm an analyst on the US Medical Supplies and Devices team. And this is day two of the Jefferies twenty twenty five New York Health Care Conference. This is a fireside chat with TeleBio. And from the company, we have Tony Koblish, founder, president, and CEO and Roberto Kuka, chief operating officer and CFO. Gentlemen, thank you for joining us today. Speaker1 Thank yo ...

Moleculin Biotech (MBRX) Update / Briefing June 05, 2025 08:30 AM ET Speaker0 Hello, and welcome to the Molecular Biotech Key Opinion Leader Webcast to discuss the company's positive top line efficacy results from its MB-one hundred seven U. S. Phase 1btwo clinical trial evaluating an antiomycin for the treatment of soft tissue sarcoma lung metastases. At this time, I'd like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations or future proje ...